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A Symposium for Medical and Pharmacy Directors,  
Physicians, Pharmacists, and Case Managers 
 
Continuing Education for Physicians and Pharmacists 
 
Complimentary Registration 
Thursday, September 14, 7:30 a.m. to 4:30 p.m. 
Hotel Sofitel, Philadelphia, PA 
 
Program Directors: David B. Nash, MD, MBA, Associate Dean, Jefferson Medical 
College and Director, Office of Health Policy and Clinical Outcomes; Geno J. Merli, 
MD, Ludwig A. Kind Professor and Director, Division of Internal Medicine and Vice 
Chairman , Primary Care, Jefferson Medical College. 
 
This one-day program will feature national experts who will present evidence of the 
economic, clinical and humanistic outcomes regarding the use and implications of low 
molecular weight heparin (LMWH). Representing different perspectives within the 
healthcare environment (the managed care organization, the integrated delivery 
system, the economist, the physician, the pharmacist) the speakers will report on 
studies and clinical experiences with LMWH and traditional unfractionated heparin.  
 
Jefferson Medical College of Thomas Jefferson University, as a member of the 
Consortium for Academic Continuing Medical Education, is accredited by the 
Accreditation Council for Continuing Medical Education to sponsor continuing medical 
education for physicians. 
 
This program is supported by an unrestricted grant from Aventis Pharmaceuticals.   
 
To receive a program brochure please call 215-955-6969. 
 
